Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Long-Term Investments (2020 - 2025)

Mirum Pharmaceuticals has reported Long-Term Investments over the past 4 years, most recently at $8.1 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $8.1 million for Q4 2025, down 35.29% from a year ago — trailing twelve months through Dec 2025 was $8.1 million (down 35.29% YoY), and the annual figure for FY2025 was $8.1 million, down 35.29%.
  • Long-Term Investments for Q4 2025 was $8.1 million at Mirum Pharmaceuticals, up from $2.5 million in the prior quarter.
  • Over the last five years, Long-Term Investments for MIRM hit a ceiling of $20.9 million in Q1 2025 and a floor of $2.5 million in Q3 2025.
  • Median Long-Term Investments over the past 3 years was $13.8 million (2021), compared with a mean of $12.2 million.
  • Peak annual rise in Long-Term Investments hit 0.22% in 2025, while the deepest fall reached 73.5% in 2025.
  • Mirum Pharmaceuticals' Long-Term Investments stood at $5.0 million in 2021, then surged by 151.37% to $12.5 million in 2024, then plummeted by 35.29% to $8.1 million in 2025.
  • The last three reported values for Long-Term Investments were $8.1 million (Q4 2025), $2.5 million (Q3 2025), and $17.1 million (Q2 2025) per Business Quant data.